Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ? 50%: Results from EMPOWER-Lung 1 study.

Basit Öğe Kaydı
dc.authoridBondarenko, Igor/0000-0002-7071-2471
dc.authoridBondarenko, Igor/0000-0002-6428-8651
dc.authoridBrady, Keri J. S./0000-0001-6417-0840
dc.authorwosidBondarenko, Igor/U-5156-2017
dc.authorwosidBondarenko, Igor/V-2431-2019
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.authorwosidBrady, Keri J. S./K-4463-2017
dc.contributor.authorGumus, Mahmut
dc.contributor.authorChen, Chieh-I
dc.contributor.authorIvanescu, Cristina
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorBondarenko, Igor
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorGogishvili, Miranda
dc.date.accessioned2024-06-12T11:22:27Z
dc.date.available2024-06-12T11:22:27Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.descriptionVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 04-08, 2021 -- ELECTR NETWORKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc; Sanofien_US
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc, and Sanofien_US
dc.identifier.doi10.1200/JCO.2021.39.15_suppl.9078
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://doi.org/10.1200/JCO.2021.39.15_suppl.9078
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25941
dc.identifier.volume39en_US
dc.identifier.wosWOS:000708120605058en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titlePatient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ? 50%: Results from EMPOWER-Lung 1 study.en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu